Similar to the effect in lung cancer, COMMD1 exerts an anti-tumor effect in malignant tumors, including prostate cancer (76), diffuse large B-cell lymphoma (77), head and neck squamous-cell carcinoma (HNSCC) (78), and neuroblastoma (79). Here, COMMD1 is linked to prostate carcinoma.